NovoCure (BMV:NVCR N) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

NVCR N Aperçu des actions

An oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally.

A propos de l'entreprise

NVCR N analyse fondamentale
Score flocon de neige
Évaluation	1/6
Croissance future	1/6
Performances passées	0/6
Santé financière	5/6
Dividendes	0/6

Récompenses

Les revenus devraient augmenter 7.1% par an

Analyse des risques

Les bénéfices devraient diminuer en moyenne de 5% par an au cours des 3 prochaines années

Les actions sont très illiquides

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

NovoCure Limited Concurrents

Shinva Medical InstrumentLtd

SHSE:600587

CN¥11.6b

Fukuda Denshi

TSE:6960

JP¥222.0b

MeHow Innovative

SZSE:301363

CN¥13.9b

Integra LifeSciences Holdings

NasdaqGS:IART

US$1.4b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour NovoCure
Historique des cours de bourse
Prix actuel de l'action	US$275.39
Plus haut sur 52 semaines	US$2,140.47
Plus bas sur 52 semaines	US$275.39
Bêta	0.52
1Variation sur 1 mois	0%
Variation sur 3 mois	n/a
Variation sur 1 an	n/a
3Variation sur 3 ans	n/a
Variation sur 5 ans	n/a
Évolution depuis l'introduction en bourse	-86.68%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	NVCR N	MX Medical Equipment	MX Marché
7D	0%	0%	0%
1Y	n/a	0%	0%

Rendement vs Industrie: Données insuffisantes pour déterminer la performance de NVCR N par rapport au secteur MX Medical Equipment.

Rendement vs marché: Données insuffisantes pour déterminer la performance de NVCR N par rapport au marché MX.

Volatilité des prix

Is NVCR N's price volatile compared to industry and market?
NVCR N volatility
NVCR N Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Cours de l'action stable: NVCR N n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: Données insuffisantes pour déterminer l'évolution de la volatilité de NVCR N au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2000	1,320	Asaf Danziger	www.novocure.com

NovoCure Limited Résumé des fondamentaux

Comment les bénéfices et les revenus de NovoCure se comparent-ils à sa capitalisation boursière ?
NVCR N statistiques fondamentales
Capitalisation boursière	Mex$27.09b
Bénéfices(TTM)	-Mex$3.35b
Recettes(TTM)	Mex$8.56b

3.2x

Ratio P/S

-8.1x

Ratio P/E

Le site NVCR N est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
NVCR N compte de résultat (TTM)
Recettes	US$503.98m
Coût des recettes	US$124.00m
Marge brute	US$379.98m
Autres dépenses	US$577.25m
Les revenus	-US$197.27m

Derniers bénéfices déclarés

Sep 30, 2023

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-1.85
Marge brute	75.40%
Marge bénéficiaire nette	-39.14%
Ratio dettes/capitaux propres	144.3%

Quelles ont été les performances à long terme de NVCR N?

Voir les performances historiques et les comparaisons

NVCR N Aperçu des actions

Récompenses

Analyse des risques

NovoCure Limited Concurrents

SHSE:600587

CN¥11.6b

TSE:6960

JP¥222.0b

SZSE:301363

CN¥13.9b

NasdaqGS:IART

US$1.4b

Historique des prix et performances

Nouvelles et mises à jour récentes

Novocure Announces CEO Changes, Effective January 1, 2025

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index

NovoCure Limited to Report Q2, 2024 Results on Jul 25, 2024

Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial

Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany

NovoCure Limited announced that it expects to receive $400 million in funding

Recent updates

Novocure Announces CEO Changes, Effective January 1, 2025

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index

NovoCure Limited to Report Q2, 2024 Results on Jul 25, 2024

Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial

Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

Chief Financial Officer recently sold Mex$589k worth of stock

Second quarter 2023 earnings released: US$0.54 loss per share (vs US$0.23 loss in 2Q 2022)

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Chief Operating Officer recently sold Mex$35m worth of stock

Chief Human Resources Officer recently sold Mex$383k worth of stock

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.56 loss in FY 2021)

Insufficient new directors

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Novocure Announces Executive Changes

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Insufficient new directors

Insufficient new directors

Third quarter 2022 earnings released: US$0.25 loss per share (vs US$0.13 loss in 3Q 2021)

Insufficient new directors

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

NovoCure Limited to Report Q3, 2022 Results on Oct 27, 2022

Insufficient new directors

Executive Chairman recently sold Mex$1.2m worth of stock

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 2Q 2021)

Insufficient new directors

NovoCure Limited to Report Q2, 2022 Results on Jul 28, 2022

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Now 20% undervalued after recent price drop

Chief Medical Officer recently sold Mex$5.4m worth of stock

Insufficient new directors

NovoCure Limited, Annual General Meeting, Jun 08, 2022

NovoCure Limited to Report Q1, 2022 Results on Apr 28, 2022

General Counsel recently sold Mex$4.6m worth of stock

Insufficient new directors

Novocure Announces Resignation of Todd Longsworth as General Counsel

Insufficient new directors

President recently bought Mex$11m worth of stock

Insufficient new directors

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer

Rendement pour les actionnaires

Volatilité des prix

À propos de l'entreprise

NovoCure Limited Résumé des fondamentaux